Silencing of CDK5 Reduces Neurofibrillary Tangles in Transgenic Alzheimer's Mice

Alzheimer's disease is a major cause of dementia for which treatments remain unsatisfactory. Cyclin-dependent kinase 5 (CDK5) is a relevant kinase that has been hypothesized to contribute to the tau pathology. Several classes of chemical inhibitors for CDK5 have been developed, but they generally lack the specificity to distinguish among various ATP-dependent kinases. Therefore, the efficacy of these compounds when tested in animal models cannot definitively be attributed to an effect on CDK5. However, RNA interference (RNAi) targeting of CDK5 is specific and can be used to validate CDK5 as a possible treatment target. We delivered a CDK5 RNAi by lentiviral or adenoassociated viral vectors and analyzed the results in vitro and in vivo. Silencing of CDK5 reduces the phosphorylation of tau in primary neuronal cultures and in the brain of wild-type C57BL/6 mice. Furthermore, the knockdown of CDK5 strongly decreased the number of neurofibrillary tangles in the hippocampi of triple-transgenic mice (3×Tg-AD mice). Our data suggest that this downregulation may be attributable to the reduction of the CDK5 availability in the tissue, without affecting the CDK5 kinase activity. In summary, our findings validate CDK5 as a reasonable therapeutic target for ameliorating tau pathology.

[1]  K. Tomizawa,et al.  An Isoform of the Neuronal Cyclin-dependent Kinase 5 (Cdk5) Activator (*) , 1995, The Journal of Biological Chemistry.

[2]  David S. Park,et al.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Gingrich,et al.  Oxidative stress is the new stress , 2005, Nature Medicine.

[4]  K. Titani,et al.  Proline-directed and Non-proline-directed Phosphorylation of PHF-tau (*) , 1995, The Journal of Biological Chemistry.

[5]  F. Gage,et al.  In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector , 1996, Science.

[6]  B. Davidson,et al.  Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. , 2008, RNA.

[7]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[8]  E. Mandelkow,et al.  Abnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and cdk5 , 1993, FEBS letters.

[9]  J. Ávila,et al.  Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus , 2004, Molecular and Cellular Neuroscience.

[10]  Jane Endicott,et al.  Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. , 2003, Journal of medicinal chemistry.

[11]  J. Carrascosa,et al.  Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells , 2003, Journal of Virology.

[12]  M. Glicksman,et al.  Kinetic studies of Cdk5/p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors. , 2008, Biochemistry.

[13]  R. Zufferey,et al.  Production of High‐Titer Lentiviral Vectors , 2000 .

[14]  R. Kotin,et al.  Insect cells as a factory to produce adeno-associated virus type 2 vectors. , 2002, Human gene therapy.

[15]  K. Imahori,et al.  A cdc2‐related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline‐directed protein kinase associated with microtubule , 1993, FEBS letters.

[16]  W. Albers,et al.  A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons , 2005, EMBO Journal.

[17]  Khadija Iqbal,et al.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. , 2008, Current medicinal chemistry.

[18]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[19]  Bernhard P. Wrobel,et al.  Multiple View Geometry in Computer Vision , 2001 .

[20]  Li-Huei Tsai,et al.  Aberrant Cdk5 Activation by p25 Triggers Pathological Events Leading to Neurodegeneration and Neurofibrillary Tangles , 2003, Neuron.

[21]  G L Trainor,et al.  Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. , 2000, Journal of medicinal chemistry.

[22]  J. Trojanowski,et al.  Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. , 2006, Annual review of pathology.

[23]  R. Aebersold,et al.  A brain-specific activator of cyclin-dependent kinase 5 , 1994, Nature.

[24]  Li-Huei Tsai,et al.  A decade of CDK5 , 2001, Nature Reviews Molecular Cell Biology.

[25]  Andrew Zisserman,et al.  Multiple View Geometry in Computer Vision (2nd ed) , 2003 .

[26]  Edward H. Adelson,et al.  A multiresolution spline with application to image mosaics , 1983, TOGS.

[27]  S. Elledge,et al.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Vladimir Kolmogorov,et al.  An Experimental Comparison of Min-Cut/Max-Flow Algorithms for Energy Minimization in Vision , 2004, IEEE Trans. Pattern Anal. Mach. Intell..

[29]  A. Clark,et al.  Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain , 1999, Neuroscience Research.

[30]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[31]  Paul Greengard,et al.  Pharmacological inhibitors of cyclin-dependent kinases. , 2002, Trends in pharmacological sciences.

[32]  I. Grundke‐Iqbal,et al.  Tau pathology in Alzheimer disease and other tauopathies. , 2005, Biochimica et biophysica acta.

[33]  S. Thummanagoti,et al.  A novel approach to cyclin-dependent kinase 5/p25 inhibitors: A potential treatment for Alzheimer's disease. , 2007, Bioorganic & medicinal chemistry.

[34]  J. Julien,et al.  Deregulation of Cdk5 in a Mouse Model of ALS Toxicity Alleviated by Perikaryal Neurofilament Inclusions , 2001, Neuron.

[35]  Vladimir Kolmogorov,et al.  An experimental comparison of min-cut/max- flow algorithms for energy minimization in vision , 2001, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[36]  A. Fattaey,et al.  CDK inhibition and cancer therapy. , 1999, Current opinion in genetics & development.

[37]  I. Martins,et al.  Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  Minh Dang Nguyen,et al.  Cyclin-Dependent Kinase 5 in Amyotrophic Lateral Sclerosis , 2003, Neurosignals.

[39]  P. Davies,et al.  Deregulation of cdk5, Hyperphosphorylation, and Cytoskeletal Pathology in the Niemann–Pick Type C Murine Model , 2002, The Journal of Neuroscience.

[40]  I. Churcher.  Tau therapeutic strategies for the treatment of Alzheimer's disease. , 2006, Current topics in medicinal chemistry.

[41]  K. Ishiguro,et al.  Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25* , 2000, The Journal of Biological Chemistry.

[42]  P. Fischer.  Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. , 2001, Current opinion in drug discovery & development.

[43]  Y. Shaham,et al.  Molecular neuroadaptations in the accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine self‐administration in rats , 2003, Journal of neurochemistry.

[44]  M. Pallàs,et al.  The role of CDK5/P25 formation/inhibition in neurodegeneration. , 2006, Drug news & perspectives.

[45]  P. L. Peng,et al.  Deregulation of HDAC1 by p25/Cdk5 in Neurotoxicity , 2008, Neuron.

[46]  L Meijer,et al.  Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. , 2000, Chemistry & biology.

[47]  D. Burk,et al.  The Determination of Enzyme Dissociation Constants , 1934 .

[48]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[49]  G L Snyder,et al.  Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. , 2000, European journal of biochemistry.

[50]  Jerry H. Wang,et al.  Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors , 2003, Nature Neuroscience.

[51]  P. Greengard,et al.  Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation , 2007, Nature Neuroscience.

[52]  Kazuyuki Takata,et al.  Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo , 2003, Neuron.

[53]  L. Tsai,et al.  A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains , 2002, FEBS letters.

[54]  B. S. Manjunath,et al.  Multi-Focus Imaging using Local Focus Estimation and Mosaicking , 2006, 2006 International Conference on Image Processing.

[55]  Andrea Musacchio,et al.  Development of an Assay to Screen for Inhibitors of Tau Phosphorylation by Cdk5 , 2004, Journal of biomolecular screening.

[56]  L. Meijer,et al.  ATP-site directed inhibitors of cyclin-dependent kinases. , 1999, Current medicinal chemistry.

[57]  B. S. Manjunath,et al.  A Condition Number for Point Matching with Application to Registration and Postregistration Error Estimation , 2003, IEEE Trans. Pattern Anal. Mach. Intell..

[58]  Yi Li,et al.  Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases , 2009, Journal of neurochemistry.

[59]  H. Braak,et al.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads , 2004, Acta Neuropathologica.

[60]  Taro Saito,et al.  Truncation of CDK5 Activator p35 Induces Intensive Phosphorylation of Ser202/Thr205 of Human Tau* , 2002, The Journal of Biological Chemistry.

[61]  David Suter,et al.  Robust adaptive-scale parametric model estimation for computer vision , 2004, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[62]  H. Geerts,et al.  Coexpression of Human cdk5 and Its Activator p35 with Human Protein Tau in Neurons in Brain of Triple Transgenic Mice , 2001, Neurobiology of Disease.

[63]  B. S. Manjunath,et al.  A Mathematical Comparison of Point Detectors , 2004, 2004 Conference on Computer Vision and Pattern Recognition Workshop.

[64]  Heekuck Oh,et al.  Neural Networks for Pattern Recognition , 1993, Adv. Comput..

[65]  Ambuj K. Singh,et al.  Bisque: a platform for bioimage analysis and management , 2009, Bioinform..

[66]  Michael P. Mazanetz,et al.  Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases , 2007, Nature Reviews Drug Discovery.

[67]  Leila Maria Garcia Fonseca,et al.  Automatic registration and mosaicking system for remotely sensed imagery , 2003, SPIE Remote Sensing.

[68]  L. Tsai,et al.  p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5 , 1994, Nature.

[69]  B. S. Manjunath,et al.  AUTOMATIC NUCLEI DETECTION AND DATAFLOW IN BISQUIK SYSTEM , 2007 .

[70]  Kenneth Chang,et al.  Lessons from Nature: microRNA-based shRNA libraries , 2006, Nature Methods.

[71]  J. H. Wang,et al.  Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. , 1993, The Journal of biological chemistry.